Close Menu

This story has been updated to include additional information on the intended use of the assay.

NEW YORK – A recent study has provided additional evidence that the enzyme thymidine kinase-1 may serve as a biomarker of how well CDK4/6 inhibitor therapy is working in metastatic breast cancer patients. 

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.